Coexpression of oncostatin M and its receptors and evidence for STAT3 activation in human ovarian carcinomas.

The expression of oncostatin M and leukemia inhibitory factor (LIF), JAK-STAT activators and members of the interleukin-6 family of cytokines, were examined in a series of primary ovarian carcinomas using immunohistochemistry. The malignant epithelial cells of all 29 ovarian carcinomas examined expressed oncostatin M; none expressed LIF. Oncostatin M can activate two related receptors, one consisting of a low-affinity LIF receptor subunit, LIFR beta, which forms a heterocomplex with the gp130 signal transducing protein and can recognize both oncostatin M and LIF, and a second heterocomplex consisting of a subunit that specifically recognizes oncostatin M, OSMR beta, and the gp130 protein. By immunohistochemistry, 25 of 25 ovarian carcinomas examined expressed the LIFR beta subunit in the malignant epithelial cells (all samples express gp130), and two-thirds the ovarian carcinomas studied expressed OSMR beta mRNA as determined by RT-PCR. Thus oncostatin M and its receptors are commonly coexpressed in malignant ovarian epithelial cells, and represent a potential autocrine loop in this tumor type. STAT3, of one the signaling proteins downstream of the oncostatin M/LIF receptors, was found in its phosphorylated, activated form (phosphotyrosine 705 STAT3) in the malignant epithelial cells of 17 of 23 ovarian carcinomas examined (74%) as determined by immunohistochemistry; this suggests that this protein is constitutively activated in most ovarian carcinomas, as it is in many other human malignancies. Recombinant human Oncostatin M (rhOSM) can induce the transient tyrosine 705 phosphorylation of STAT3 in serum-starved LIFR beta/OSMR beta expressing ovarian carcinoma cell lines, but does not alter cell growth and effects only a modest increase in the apoptotic rate in these cultured cells. Oncostatin M and its receptors may be part of a network of cytokine systems within ovarian carcinomas that may act to maintain STAT3 in its activated form, a phenomenon associated with the malignant phenotype.

[1]  C. Guillet,et al.  Signaling of Type II Oncostatin M Receptor* , 1997, The Journal of Biological Chemistry.

[2]  J. Gauldie,et al.  Recombinant oncostatin M stimulates the production of acute phase proteins in HepG2 cells and rat primary hepatocytes in vitro. , 1992, Journal of immunology.

[3]  G. Yancopoulos,et al.  Differential activation of the extracellular signal‐regulated kinase, Jun Kinase and Janus Kinase‐Stat pathways by oncostatin M and basic fibroblast growth factor in AIDS‐derived Kaposi's sarcoma cells , 1996, AIDS.

[4]  J. Grandis,et al.  Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. , 1998, The Journal of clinical investigation.

[5]  T. Lennard,et al.  Oncostatin M, interleukin 2, interleukin 6 and interleukin 8 in breast cyst fluid , 1994, International journal of cancer.

[6]  E. Wilander,et al.  Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. , 1993, Cancer research.

[7]  H. Marquardt,et al.  Purification and characterization of cytostatic lymphokines produced by activated human T lymphocytes. Synergistic antiproliferative activity of transforming growth factor beta 1, interferon-gamma, and oncostatin M for human melanoma cells. , 1987, Journal of immunology.

[8]  J. Darnell.  STATs and gene regulation. , 1997, Science.

[9]  R. Bast,et al.  Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. , 1991, American journal of obstetrics and gynecology.

[10]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[11]  S. Bulun,et al.  Expression of transcripts of interleukin-6 and related cytokines by human breast tumors, breast cancer cells, and adipose stromal cells , 1996, Molecular and Cellular Endocrinology.

[12]  J. Darnell,et al.  Stat3 Activation Is Required for Cellular Transformation by v-src , 1998, Molecular and Cellular Biology.

[13]  D. Friend,et al.  Dual Oncostatin M (OSM) Receptors , 1996, The Journal of Biological Chemistry.

[14]  Z. Estrov,et al.  Oncostatin M-specific receptor expression and function in regulating cell proliferation of normal and malignant mammary epithelial cells. , 1998, Cytokine.

[15]  J. Turkson,et al.  STAT proteins: novel molecular targets for cancer drug discovery , 2000, Oncogene.

[16]  V. Gouilleux-Gruart,et al.  Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. , 1996, Blood.

[17]  P. Linsley,et al.  Oncostatin M as a potent mitogen for AIDS-Kaposi's sarcoma-derived cells. , 1992, Science.

[18]  R. Jove,et al.  Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[19]  Comeau,et al.  The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. , 1992, Science.

[20]  R. Jove,et al.  Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. , 1995, Science.

[21]  P. Quesenberry,et al.  Coexpression of granulocyte colony stimulating factor and its receptor in primary ovarian carcinomas. , 2001, Cancer letters.

[22]  S. Nakamura,et al.  Identification of a major growth factor for AIDS-Kaposi's sarcoma cells as oncostatin M. , 1992, Science.

[23]  J. Darnell,et al.  Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors , 1995, Science.

[24]  Taylor Murray,et al.  Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.

[25]  M. Spence,et al.  Oncostatin M-mediated transcriptional suppression of the c-myc gene in breast cancer cells. , 1997, Cancer research.

[26]  B. Groner,et al.  STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients , 1996 .

[27]  Jiayuh Lin,et al.  Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells. , 2000, Gynecologic oncology.

[28]  R. Bukowski,et al.  Resistance to interleukin 6 in human non-small cell lung carcinoma cell lines: role of receptor components. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[29]  Y. Shima,et al.  Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130 , 1994, The Journal of experimental medicine.

[30]  P. Rothman,et al.  Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. , 1997, Journal of immunology.

[31]  J. Darnell,et al.  Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. , 1994, Science.

[32]  J. Turkson,et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.

[33]  G. Todaro,et al.  Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Robert L Sutherland,et al.  Expression and function of members of the cytokine receptor superfamily on breast cancer cells , 1997, Oncogene.

[35]  S. Akira,et al.  Interleukin-6 family of cytokines and gp130. , 1995, Blood.

[36]  G. Yancopoulos,et al.  Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. , 1994, Science.

[37]  T. Rose,et al.  Oncostatin M is a differentiation factor for myeloid leukemia cells. , 1992, Journal of immunology.

[38]  B. Bonavida,et al.  Oncostatin M (OM) promotes the growth of DU 145 human prostate cancer cells, but not PC-3 or LNCaP, through the signaling of the OM specific receptor. , 1999, Anticancer research.

[39]  F. Balkwill,et al.  Epithelial ovarian cancer: a cytokine propelled disease? , 1991, British Journal of Cancer.

[40]  G. Ciliberto,et al.  Blocking signaling through the gp130 receptor chain by interleukin‐6 and oncostatin M inhibits PC‐3 cell growth and sensitizes the tumor cells to etoposide and cisplatin‐mediated cytotoxicity , 1999, Cancer.

[41]  M. Jaroszeski,et al.  Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. , 1999, Cancer research.

[42]  T. Rose,et al.  Oncostatin M is a member of a cytokine family that includes leukemia-inhibitory factor, granulocyte colony-stimulating factor, and interleukin 6. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[43]  K. Kuropatwinski,et al.  Influence of Subunit Combinations on Signaling by Receptors for Oncostatin M, Leukemia Inhibitory Factor, and Interleukin-6* , 1997, The Journal of Biological Chemistry.

[44]  M. Pike,et al.  "INCESSANT OVULATION" AND OVARIAN CANCER , 1979, The Lancet.

[45]  Activation of the JAK-STAT signal transduction pathway by oncostatin-M cultured human and mouse osteoblastic cells. , 1996, Endocrinology.

[46]  R. Jove,et al.  Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. , 1998, Journal of biomedical science.

[47]  J. Westendorf,et al.  Growth regulatory pathways in myeloma. Evidence for autocrine oncostatin M expression. , 1996, Journal of immunology.

[48]  P. Quesenberry,et al.  Interleukin-11 receptor expression in primary ovarian carcinomas. , 2001, Gynecologic oncology.

[49]  A. Gao,et al.  Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. , 2000, Cancer research.